Brisbane, Calif. — August 8, 2025 — Leads & Copy — Vera Therapeutics, Inc. (Nasdaq: VERA) announced on August 4, 2025, that its Compensation Committee granted inducement awards to eight new employees. These awards consist of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock under the Vera Therapeutics, Inc. 2024 Inducement Plan.
The Compensation Committee approved these awards as an inducement material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option, granted on August 4, 2025, has an exercise price of $20.45 per share, equivalent to Vera’s closing trading price on the grant date. The stock options vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly over the following 36 months, contingent upon continued service. The RSU awards also vest over four years, with 25% vesting annually on each anniversary of August 20, 2025, subject to continued service. The awards are governed by the terms and conditions of the Inducement Plan and the applicable award agreements.
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Their lead product candidate is atacicept, a self-administered fusion protein that blocks BAFF and APRIL, reducing autoantibodies in autoimmune diseases like IgAN and lupus nephritis. Vera is also developing MAU868, a monoclonal antibody targeting BK virus infections, and holds an exclusive license for VT-109, a next-generation fusion protein targeting BAFF and APRIL.
Investor Contact: Joyce Allaire, LifeSci Advisors, 212-915-2569, jallaire@lifesciadvisors.com
Media Contact: Debra Charlesworth, Vera Therapeutics, 415-854-8051, corporatecommunications@veratx.com
Source: Vera Therapeutics, Inc.
